Financial Advocates Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Financial Advocates Investment Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,681	Closed	-$198K	–	300
2025 Q2	$198K	Sell	1,681 -507	-23%	-$62.2K	0.02%	588
2025 Q1	$263K	Sell	2,188 -7,751	-78%	-$1.05M	0.02%	591
2024 Q4	$1.31M	Sell	9,939 -20	-0.2%	-$2.81K	0.07%	239
2024 Q3	$1.45M	Buy	9,959 +994	+11%	+$144K	0.08%	230
2024 Q2	$1.23M	Buy	8,965 +6,959	+347%	+$929K	0.08%	247
2024 Q1	$269K	Sell	2,006 -5,720	-74%	-$781K	0.02%	626
2023 Q4	$429K	Buy	7,726 +4,220	+120%	+$515K	0.03%	459
2023 Q3	$389K	Sell	3,506 -2,499	-42%	-$318K	0.03%	470
2023 Q2	$762K	Sell	6,005 -285	-5%	-$37K	0.05%	311
2023 Q1	$812K	Sell	6,290 -557	-8%	-$72.9K	0.06%	328
2022 Q4	$776K	Buy	6,847 +2,834	+71%	+$366K	0.06%	344
2022 Q3	$469K	Sell	4,013 -524	-12%	-$65.1K	0.04%	434
2022 Q2	$534K	Sell	4,537 -5,885	-56%	-$699K	0.04%	387
2022 Q1	$1.36M	Sell	10,422 -3,278	-24%	-$427K	0.09%	244
2021 Q4	$2.09M	Buy	13,700 +3,819	+39%	+$591K	0.13%	192
2021 Q3	$1.6M	Sell	9,881 -4,179	-30%	-$703K	0.11%	227
2021 Q2	$2.3M	Buy	14,060 +376	+3%	+$57.9K	0.15%	160
2021 Q1	$2.06M	Buy	13,684 +1,139	+9%	+$181K	0.15%	170
2020 Q4	$1.89M	Sell	12,545 -1,867	-13%	-$267K	0.13%	184
2020 Q3	$1.65M	Buy	14,412 +1,272	+10%	+$173K	0.14%	159
2020 Q2	$1.27M	Buy	13,140 +6,106	+87%	+$778K	0.12%	206
2020 Q1	$758K	Sell	7,034 -1,293	-16%	-$149K	0.11%	216
2019 Q4	$1M	Sell	8,327 -549	-6%	-$61.3K	0.11%	210
2019 Q3	$883K	Sell	8,876 -999	-10%	-$105K	0.1%	208
2019 Q2	$1.08M	Sell	9,875 -1,506	-13%	-$160K	0.12%	176
2019 Q1	$1.27M	Buy	11,381 +4,653	+69%	+$510K	0.16%	150
2018 Q4	$649K	Buy	6,728 +1,791	+36%	+$190K	0.09%	214
2018 Q3	$602K	Buy	4,937 +113	+2%	+$13.3K	0.07%	257
2018 Q2	$533K	Sell	4,824 -129	-3%	-$13.8K	0.06%	261
2018 Q1	$529K	Buy	4,953 +11	+0.2%	+$1.22K	0.07%	249
2017 Q4	$530K	Buy	+4,942	New	+$528K	0.07%	248

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Financial Advocates Investment Management's IBB Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of iShares Biotechnology ETF (IBB) in Q3 2025, closing a stake of 1,681 shares — an estimated $198K sold.

Financial Advocates Investment Management first reported a position in IBB in Q4 2017 and held it in 31 quarters. The position peaked at $2.3M in Q2 2021. 804 funds tracked by Wall St. Rank hold IBB as of Q3 2025.

Financial Advocates Investment Management reported no remaining iShares Biotechnology ETF position as of Q3 2025 after selling out during the quarter.
Financial Advocates Investment Management sold 1,681 iShares Biotechnology ETF shares in Q3 2025, an estimated $198K.
Financial Advocates Investment Management first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 31 quarters.
Financial Advocates Investment Management's iShares Biotechnology ETF position peaked at $2.3M in Q2 2021.
804 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.